Analyzing Alnylam Pharmaceuticals (ALNY) & The Competition

Alnylam Pharmaceuticals (NASDAQ:ALNY) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Alnylam Pharmaceuticals to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings.

Profitability

This table compares Alnylam Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	52.85%	155.33%	44.81%
Alnylam Pharmaceuticals Competitors	-12,319.70%	-407.93%	-30.95%

Analyst Recommendations

This is a summary of current recommendations for Alnylam Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0	10	15	1	2.65
Alnylam Pharmaceuticals Competitors	9903	15310	45655	1602	2.54

Alnylam Pharmaceuticals presently has a consensus target price of $305.86, indicating a potential upside of 85.33%. As a group, “Biotechnology” companies have a potential upside of 126.71%. Given Alnylam Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Alnylam Pharmaceuticals has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71 billion	$313.75 million	8.57
Alnylam Pharmaceuticals Competitors	$728.85 million	$11.28 million	-18.80

Alnylam Pharmaceuticals has higher revenue and earnings than its competitors. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Alnylam Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ competitors have a beta of -1.88, indicating that their average share price is 288% less volatile than the S&P 500.

Summary

Alnylam Pharmaceuticals beats its competitors on 10 of the 13 factors compared.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.